How many venous thromboembolism (VTE) patients do you see per month, on average?

What proportion of iliofemoral DVT cases do you perform on each system? 

• Penumbra Indigo
• Boston Scientific Angiojet
• Inari FlowTriever / ClotTriever
• Other: 

What proportion of massive / submassive PE cases do you perform on each system? 

• Penumbra Indigo
• Boston Scientific Ekos
• Inari FlowTriever / ClotTriever
• Other: 

If you answered "Other" for either question above, please specific. 

What proportion of all DVT cases do you currently treat with mechanical thrombectomy procedures?

Please explain why you prefer the interventional device for iliofemoral DVT and massive/submassive PE that you use most often?

Have you experienced any unexpected device related problems or safety issues with any mechanical thrombectomy systems? Please elaborate.

What proportion of all DVT cases do you anticipate will be treated with mechanical thrombectomy in 3 years?

What proportion of all PE cases do you currently treat with mechanical thrombectomy procedures?

What proportion of all PE cases do you anticipate will be treated with mechanical thrombectomy in 3 years?

How has your practice been affected by the recent shortage of certain contrast imaging agents?

If your practice has been affected by the recent shortages, what is your current mechanical thrombectomy procedure volume as a percentage of normal (if you practice has been unaffected, please answer 0)?

At present what proportion of your VTE cases are related to COVID-19 infections?

At peak, what proportion of your VTE cases were related to COVID-19 infections?

The PEERLESS trial is a randomized controlled trial of Inari’s ClotTriever compared with catheter directed thrombolysis for the treatment of high-risk PE. The primary endpoint is a composite of all-cause mortality, bleeding events, clinical deterioration, and ICU admission. What is the probability (%) that ClotTriever shows a statistically significant result on the primary endpoint?